Cellares and GenomeFrontier Therapeutics partnered to evaluate automated manufacturing for GF-CART01 using Cellares’ Cell Shuttle platform. The collaboration focuses on translating GenomeFrontier’s virus-free CAR T manufacturing process, emphasizing electroporation and transfection unit operation as the workflow is moved toward automation. GenomeFrontier is developing GF-CART01 for B-cell malignancies including diffuse large B-cell lymphoma and follicular lymphoma, and it is recruiting for a Phase I trial in the United States. The companies positioned the work as a path to reduce labor intensity and variability in autologous CAR T manufacturing while improving scale and reliability for clinical and future commercial demand.